Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors - Wikidata - awgldk - TriplyDB

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors

http://www.wikidata.org/entity/Q35178389

about

Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer Targeting the adaptive molecular landscape of castration-resistant prostate cancer Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation Steroid sidestep: evading androgen ablation by abiraterone.Loss of Wave1 gene defines a subtype of lethal prostate cancer Gleason Score 7 Prostate Cancers Emerge through Branched Evolution of Clonal Gleason Pattern 3 and 4.Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance.Androgen pathway resistance in prostate cancer and therapeutic implications Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients.Regulators of Androgen Action Resource: a one-stop shop for the comprehensive study of androgen receptor action.Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation.BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients Influence of Statins on Survival Outcome in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Abiraterone Acetate.Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Androgen receptor-dependent and -independent mechanisms driving prostate cancer progression: Opportunities for therapeutic targeting from multiple angles.Detection fidelity of AR mutations in plasma derived cell-free DNA Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.Androgen receptor aberrations in the era of abiraterone and enzalutamide.Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer.A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.Role of steroid receptor and coregulator mutations in hormone-dependent cancers.Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.A Pilot Study of Clinical Targeted Next Generation Sequencing for Prostate Cancer: Consequences for Treatment and Genetic Counseling.New Biomarkers for Selecting the Best Therapy Regimens in Metastatic Castration-Resistant Prostate Cancer.Androgen synthesis in prostate cancer: do all roads lead to Rome?Characterization of an Abiraterone Ultraresponsive Phenotype in Castration-Resistant Prostate Cancer Patient-Derived Xenografts.A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine.Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer Application of liquid biopsies to identify genomic factors associated with therapy resistance in castration resistant prostate cancer.Clinical relevance of androgen receptor alterations in prostate cancer.

P2860

Q26739708-E4A6E07A-D958-470A-ACA0-2E086FB870BA Q26748538-BEE91ACF-2096-4D05-A982-FF4556D1CD84 Q26751237-2118103F-05A6-41C9-B9E4-9C23F66BC3A3 Q26777310-DE10E7B0-9839-4308-8D9D-B0B57196D36D Q26795625-F27A5780-6C46-40DA-9628-DD3F3172813D Q27022821-A128FE18-F9C8-4EF2-BE40-9EE875325145 Q28067556-45339A2E-7FE3-4381-8F3A-242385D30B21 Q28817905-FBE07DCA-488D-4B7B-ADB4-9A3DBD28FB81 Q35178362-D0611BB2-46F6-4B6D-BDE7-982B0996CD23 Q35828579-6EE4EFDD-0844-4995-9D8B-4F3268F3D72A Q36259221-F362AAEB-FD10-4834-9750-708DDA267649 Q36398998-1BF90E01-18CF-4C76-9F06-71B6BACD002E Q36416370-5A33707D-8A3C-4FF1-8388-3B231B1E1411 Q36470627-8C06DAAC-9CF7-498E-B91C-078323D929DA Q36508759-1B417F62-450A-4B3A-831C-33C8FDDE1D1A Q36578330-9712F869-E181-40E2-A442-06D556AE700C Q36738961-51629F07-8752-41B9-9C7B-C929AAACBADE Q36905832-613965B7-4CBB-44E0-8F55-D4ED4E2DFF3E Q37226646-ECFB672C-B2A9-4A39-B0B8-276E0D588242 Q37496652-6F719B4E-482A-4789-8921-E12D182DC857 Q37709535-A165DF5A-4235-48F7-99D3-D571C3630DBE Q37716596-24A6B7DF-4571-4F9B-80D8-FA2A19453145 Q38375252-246654E6-B974-4941-8EE2-0FDD31F458BD Q38534949-52AD8586-08BE-4775-88BE-8A780353DD4F Q38703676-EFB1E085-8421-45D9-8800-60A9DBC55E7B Q38723579-CCD4B7BB-9500-4A1A-B5BF-A16BE39B6603 Q38735379-7085F4E8-238D-41C6-9099-01343D03B1C1 Q38736287-3A4BF167-B056-4295-BCE0-2BD6EA4BA1FA Q38804089-A49B8D29-01B5-4912-A617-ECD58D0E3887 Q38850529-1B05FF09-72FF-4D55-AA28-75D68B99FF17 Q38994718-E456CBB1-A9FB-4364-AD6C-8E1FBFF69B2A Q39002780-C16787FD-F238-421D-BB2D-61407C0C7377 Q39085996-D6DEB21D-DE38-49C1-827B-1F186D3439E1 Q39775985-9F1E33AB-9165-4D71-B6F7-BBE76B3C6460 Q41561381-7F96AB6E-5A54-4ECB-9C9E-A2EA29485C35 Q41768007-CF320D15-DF66-4703-ACEA-75496E24D046 Q42174990-6607E78A-0CF0-4637-8D17-134368B72C60 Q42188589-79D92A8A-F94A-45AC-9FB1-9AA78A5F5158 Q42370326-B51D729B-C2AA-4CE2-B4EA-36D97C220556 Q42377108-5E461B2F-663E-4340-8E1E-4D81E93D5C3D

P2860

Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors

http://www.wikidata.org/entity/Q35178389

description

2014 nî lūn-bûn

@nan

2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Abiraterone treatment in castr ...... sive mutant androgen receptors

@ast

Abiraterone treatment in castr ...... sive mutant androgen receptors

@en

type

label

Abiraterone treatment in castr ...... sive mutant androgen receptors

@ast

Abiraterone treatment in castr ...... sive mutant androgen receptors

@en

prefLabel

Abiraterone treatment in castr ...... sive mutant androgen receptors

@ast

Abiraterone treatment in castr ...... sive mutant androgen receptors

@en

P1433

Q35178389-11DB3E90-436D-422C-A62A-FFDF5CAD489F

P1476

Q35178389-2B6CAF31-5D2F-4E07-91E5-A27FCDB3E5C0

P2093

Q35178389-06E062C4-9AF3-4613-9775-0BD3D8542378

Q35178389-2DE98151-A112-4635-A879-E1F2DB997519

Q35178389-2E7BEFBF-F5FB-4AF9-AF4E-CEB6CAB09609

Q35178389-3896BDBB-3925-4EF9-B39C-389CCDEA1963

Q35178389-47CD01A9-E61C-4284-A8F0-F5E198B38BD1

Q35178389-78661EBC-427D-438D-8DA3-5905EC5445EA

Q35178389-8F122F30-0CBA-4021-94D9-D0BF9FF1B05D

Q35178389-9D442A37-F863-421A-AC65-644B78A018FE

Q35178389-9F3683D4-8428-4317-99E6-3A11C8D989CD

Q35178389-A0172543-6620-426B-9FC9-F33C067A523B

P2860

Q35178389-1CF420E5-69F3-40FD-90D9-75A138A9A0F4

Q35178389-206A56C9-59AB-4891-B8EF-1F2D27E3B5C8

Q35178389-234DE066-3571-421B-9588-F46E8B5945D4

Q35178389-28AFE30D-CB85-4A37-ADC5-13094B2EE24F

Q35178389-507A7831-998E-406B-9923-D998DF4C3DEC

Q35178389-50BE1ACE-B7E8-47CE-99CA-6261BACD7A55

Q35178389-52373834-C0F5-4158-8647-7BA00F7CF8F9

Q35178389-52C95092-94B9-4EBA-8A2F-7B3B0A9F21E0

Q35178389-5B48F5F1-52F8-4BC0-A3E4-B112677F656A

Q35178389-5FA19716-730A-4F55-A6B2-550E9FADCBEF

P304

Q35178389-C4C5CB42-6EE5-46BE-95D7-0534103F7999

P31

Q35178389-84C88EDD-A66A-4979-94EE-39694215C59C

P356

Q35178389-90191A92-D2DE-49CC-932D-1C9691E125D8

P407

Q35178389-B22ADA42-80EF-4DB3-9DB9-827E362377FF

P433

Q35178389-0A256805-42A8-4BC0-8C99-067961D9A276

P478

Q35178389-EF583E13-98A6-45B0-B739-4360910796B2

P50

Q35178389-0B5636D3-12A2-4048-AC13-C258E0D20E26

Q35178389-89951833-EE91-4E84-B762-C1371FFC69B7

Q35178389-FDD31EAD-3480-4F31-8858-050CE61E3CDD

P577

Q35178389-B63F8A0D-23F1-4C0C-8521-7AADECF85363

P698

Q35178389-63A7C364-F7E3-4017-A6CC-DF2DF90C21A1

P932

Q35178389-8195B6E6-4E3E-49AA-8716-1D2ACB3D16B5

P356

1078-0432.CCR-14-1220

P1433

Clinical Cancer Research

P1476

Abiraterone treatment in castr ...... sive mutant androgen receptors

@en

P2093

Adam G Sowalsky

http://www.w3.org/2001/XMLSchema#string

Changmeng Cai

http://www.w3.org/2001/XMLSchema#string

Eddy J Chen

http://www.w3.org/2001/XMLSchema#string

Glenn J Bubley

http://www.w3.org/2001/XMLSchema#string

Huihui Ye

http://www.w3.org/2001/XMLSchema#string

Lawrence D True

http://www.w3.org/2001/XMLSchema#string

Olga Voznesensky

http://www.w3.org/2001/XMLSchema#string

Patricia Troncoso

http://www.w3.org/2001/XMLSchema#string

Peter S Nelson

http://www.w3.org/2001/XMLSchema#string

Rachel Schaefer

http://www.w3.org/2001/XMLSchema#string

P2860

Abiraterone in metastatic prostate cancer without previous chemotherapy

VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing

Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.

A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509.

The Sequence Alignment/Map format and SAMtools

Overcoming mutation-based resistance to antiandrogens with rational drug design

Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration

Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3

Abiraterone and increased survival in metastatic prostate cancer

P304

1273-1280

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-1220

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Philip W. Kantoff

Mary-Ellen Taplin

P577

2014-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25320358

http://www.w3.org/2001/XMLSchema#string

P932

4359958

http://www.w3.org/2001/XMLSchema#string